I am not so sure that the plan would be to simply sell off the drug completely. It is certainly within the realm of possibility that they partner rather then sell outright. Many have also suggested trying to sell a single indication of Brilacidin for instance which could be a possibility as illustrated by the " medical device coatings" language that Cellceutix would retain all other medical uses.

At the very least the mere possibility of other indications would probably attract a higher sales price if your scenario is correct. I wasn't really looking for other indications when I ran across the info. I was looking for the MOA for Prurisol against Psoriosis so it was just worth considering that there could be more down the road for Prurisol if it proves itself.